Tom Davidson is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman. He serves on the Firm’s Executive Committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Mr. Davidson is focused on building a world class Mergers & Acquisitions business at Leerink Partners.
Over the last decade, Mr. Davidson has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.
Prior to joining the Firm in 2024, from PJT Partners, where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.
Mr. Davidson earned a B.A. in Economics from Yale University, summa cum laude and Phi Beta Kappa and an MBA from the Wharton School of the University of Pennsylvania. Mr. Davidson is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.
Dan Dubin, M.D., is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman and sits on the Firm’s Executive Committee.
For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.
Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.
Christine Del Corsano serves as the Global Chief Operating Officer of Investment Banking at Leerink Partners. She brings over 25 years of experience in finance and healthcare investment banking.
Mrs. Del Corsano rejoined the Firm in 2025, after serving as Chief Financial Officer of Enavate Sciences, where she was responsible for finance and operations, and partnered with executive leadership on corporate strategy and supporting portfolio company operations.
During her earlier tenure at Leerink Partners, Mrs. Del Corsano was a Managing Director and Business Manager, responsible for managing the overall operations of the department including strategic planning, financial and business reporting and analytics, people management and recruiting. Prior to Leerink Partners, she held senior leadership positions at Merrill Lynch, including COO of the Healthcare, Energy & Power, and Technology Investment Banking groups.
Mrs. Del Corsano earned her B.S. in Accounting from St. John’s University.
